WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 462095
CAS#: 95851-37-9
Description: Kadsurenone is a platelet-activating factor receptor antagonist from Chinese herbal plant, haifenteng. It is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway.
MedKoo Cat#: 462095
Name: Kadsurenone
CAS#: 95851-37-9
Chemical Formula: C21H24O5
Exact Mass: 356.1624
Molecular Weight: 356.418
Elemental Analysis: C, 70.77; H, 6.79; O, 22.44
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Kadsurenone; Denudatin B
IUPAC/Chemical Name: 6(2H)-Benzofuranone, 2-(3,4-dimethoxyphenyl)-3,3a-dihydro-3a-methoxy-3-methyl-5-(2-propenyl)-, (2S-(2alpha,3beta,3aalpha))-
InChi Key: VDYACOATPFOZIO-UBWHGVKJSA-N
InChi Code: InChI=1S/C21H24O5/c1-6-7-15-12-21(25-5)13(2)20(26-19(21)11-16(15)22)14-8-9-17(23-3)18(10-14)24-4/h6,8-13,20H,1,7H2,2-5H3/t13-,20+,21+/m1/s1
SMILES Code: O=C1C(CC=C)=C[C@]2(OC)[C@H](C)[C@@H](C3=CC=C(OC)C(OC)=C3)OC2=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 356.418 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes. G. Lambrecht, M. J. Parnham Br J Pharmacol. 1986 Feb; 87(2): 287–289. doi: 10.1111/j.1476-5381.1986.tb10816.x PMCID: PMC1916546
2: Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. T Y Shen, S B Hwang, M N Chang, T W Doebber, M H Lam, M S Wu, X Wang, G Q Han, R Z Li Proc Natl Acad Sci U S A. 1985 Feb; 82(3): 672–676. doi: 10.1073/pnas.82.3.672 PMCID: PMC397107
3: Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation. M. J. Parnham, C. Bittner, G. Lambrecht Br J Pharmacol. 1989 Oct; 98(2): 574–580. doi: 10.1111/j.1476 5381.1989.tb12631.x PMCID: PMC1854744
4: Enhanced human monocyte cytotoxicity by platelet-activating factor. F H Valone, R Philip, R J Debs Immunology. 1988 Aug; 64(4): 715–718. PMCID: PMC1384996
5: Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathwayTianhui Hou, Yan Lou, Shichang Li, Chenglong Zhao, Yingzheng Ji, Dongsheng Wang, Liang Tang, Ming Zhou, Wei Xu, Ming Qian, Zhipeng Wu, Jian Zhao, Haifeng Wei, Zhenxi Li, Jianru Xiao Oncol Lett. 2018 Aug; 16(2): 2255–2262.
Published online 2018 Jun 8. doi: 10.3892/ol.2018.8935 PMCID: PMC6036417
6: A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus Dan He, Jian-Hua Huang, Zhe-Yu Zhang, Qing Du, Wei-Jun Peng, Rong Yu, Si-Fang Zhang, Shui-Han Zhang, Yu-Hui Qin Drug Des Devel Ther. 2019; 13: 3989–4005. Published online 2019 Nov 28. doi: 10.2147/DDDT.S216644Correction in: Drug Des Devel Ther. 2020; 14: 949. PMCID: PMC6890936
7: Antagonism of Paf-induced oedema formation in rabbit skin: a comparison of different antagonists. P. G. Hellewell, T. J. Williams Br J Pharmacol. 1989 May; 97(1): 171–180. doi: 10.1111/j.1476-5381.1989.tb11939.x PMCID: PMC1854485
8: The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation. D. Aked, S. J. Foster, A. Howarth, M. E. McCormick, H. C. Potts Br J Pharmacol. 1986 Oct; 89(2): 431–438. doi: 10.1111/j.1476-5381.1986.tb10277.x PMCID: PMC1917011
9: Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor. F H Valone, N M Ruis Immunology. 1992 May; 76(1): 24–29. PMCID: PMC1421731
10: Oxetane Synthesis through the Paternò-Büchi Reaction Maurizio D’Auria, Rocco Racioppi Molecules. 2013 Sep; 18(9): 11384 11428. Published online 2013 Sep 16. doi: 10.3390/molecules180911384 PMCID: PMC6269742
